2022 infant formula shortage occurred due to FDA's inadequate oversight and communication, despite warning signs and whistleblowers.

The FDA failed to address concerns about a major infant formula maker before a 2022 shortage, according to the Department of Health and Human Services' inspector general. The agency lacked sufficient oversight and communication, which hindered their response. An investigation revealed that the FDA disregarded warning signs, including severe illnesses in babies and whistleblower complaints.